GYKI-47261 | CAS# 220445-20-5 | 1217049-32-5 | AMPA antagonist

MedKoo Cat#: 526610 | Name: GYKI-47261

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GYKI-47261 is a AMPA antagonist and a CYP2E1 inducer. GYKI-47261 showed broad spectrum of anticonvulsive and excellent neuroprotective effect. AMPA and NMDA receptors, abundantly expressed on striatal medium spiny neurons, have been implicated in the regulation of corticostriatal synaptic efficacy.

Chemical Structure

GYKI-47261

CAS# 220445-20-5 (free base)

Theoretical Analysis

MedKoo Cat#: 526610

Name: GYKI-47261

CAS#: 220445-20-5 (free base)

Chemical Formula: C18H15ClN4

Exact Mass: 322.0985

Molecular Weight: 322.80

Elemental Analysis: C, 66.98; H, 4.68; Cl, 10.98; N, 17.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

220445-20-5 (free base) 1217049-32-5 (HCl)

Synonym

GYKI-47261; GYKI 47261; GYKI47261.

IUPAC/Chemical Name

4-(8-chloro-2-methyl-11H-benzo[e]imidazo[1,2-b][1,2]diazepin-6-yl)aniline

InChi Key

FPXVCCSOTAQPIV-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H15ClN4/c1-11-10-23-17(21-11)8-13-2-5-14(19)9-16(13)18(22-23)12-3-6-15(20)7-4-12/h2-7,9-10H,8,20H2,1H3

SMILES Code

NC1=CC=C(C2=NN3C(CC4=CC=C(Cl)C=C42)=NC(C)=C3)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 322.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol. 2005 Dec;196(2):422-9. Epub 2005 Oct 3. PubMed PMID: 16203001. 2: Tamási V, Hazai E, Porsmyr-Palmertz M, Ingelman-Sundberg M, Vereczkey L, Monostory K. GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer. Drug Metab Dispos. 2003 Nov;31(11):1310-4. PubMed PMID: 14570761. 3: Sólyom S. [Research on new AMPA antagonists of the 2,3-benzodiazepine type]. Acta Pharm Hung. 2001;71(1):80-7. Hungarian. PubMed PMID: 11769101. 4: Sólyom S. Research on new AMPA antagonists of 2,3-benzodiazepine type. Pharmazie. 2001 Oct;56 Suppl 1:S62-6. Review. PubMed PMID: 11686094. 5: Abrahám G, Sólyom S, Csuzdi E, Berzsenyi P, Ling I, Tarnawa I, Hámori T, Pallagi I, Horváth K, Andrási F, Kapus G, Hársing LG Jr, Király I, Patthy M, Horváth G. New non competitive AMPA antagonists. Bioorg Med Chem. 2000 Aug;8(8):2127-43. PubMed PMID: 11003158.